<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1808222520
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Vesuv
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SILDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        39.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vesuv contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE 5) inhibitors. It works by helping to relax the blood vessels in your penis, allowing blood to flow into your penis when you get sexually excited. Vesuv will only help you to get an erection if you are sexually stimulated.</p><p>Vesuv is a treatment for adult men with erectile dysfunction, sometimes known as impotence. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vesuv</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking medicines called nitrates, as the combination may lead to a dangerous fall in your blood pressure. Tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris (or &ldquo;chest pain&rdquo;). If you are not certain, ask your doctor or pharmacist.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using any of the medicines known as nitric oxide donors such as amyl nitrite (&ldquo;poppers&rdquo;), as the combination may also lead to a dangerous fall in your blood pressure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Vesuv have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe heart or liver problem.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently had a stroke or a heart attack, or if you have low blood pressure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have certain rare inherited eye diseases (such as retinitis pigmentosa).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy (NAION).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Vesuv</p><p>- If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).</p><p>- If you have a deformity of your penis or Peyronie&rsquo;s Disease.</p><p>&minus; If you have problems with your heart. Your doctor should carefully check whether your heart can take the additional strain of having sex.</p><p>&minus; If you currently have a stomach ulcer, or a bleeding problems (such as haemophilia).</p><p>&minus; If you experience sudden decrease or loss of vision, stop taking Vesuv and contact your doctor immediately.</p><p>You should not use Vesuv with any other oral or local treatments for erectile dysfunction.</p><p>You should not use Vesuv with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors.</p><p>You should not take Vesuv if you do not have erectile dysfunction.</p><p>You should not take Vesuv if you are a woman.</p><p>Special considerations for patients with kidney or liver problems</p><p>You should tell your doctor if you have kidney or liver problems. Your doctor may decide on a lower dose for you.</p><p><strong>Children and adolescents</strong></p><p>Vesuv should not be given to individuals under the age of 18.</p><p><strong>Other medicines and Vesuv</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Vesuv tablets may interfere with some medicines, especially those used to treat chest pain. In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Vesuv and when you did. Do not take Vesuv with other medicines unless your doctor tells you that you can.</p><p>You should not take Vesuv if you are taking medicines called nitrates, as the combination of these medicines may lead to a dangerous fall in your blood pressure. Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or &ldquo;chest pain&rdquo;).</p><p>You should not take Vesuv if you are using any of the medicines known as nitric oxide donors such as amyl nitrite (&ldquo;poppers&rdquo;) as the combination may also lead to a dangerous fall in your blood pressure.</p><p>Tell your doctor or pharmacist if you are already taking riociguat.</p><p>If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Vesuv.</p><p>Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly. Certain patients have experienced these symptoms when taking Vesuv with alpha-blockers. This is most likely to happen within 4 hours after taking Vesuv. To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Vesuv. Your doctor may start you on a lower dose (25 mg) of Vesuv.</p><p><strong>Vesuv with food and drink and alcohol</strong></p><p>Vesuv can be taken with or without food. However, you may find that Vesuv takes longer to start working if you take it with a heavy meal.</p><p>Drinking alcohol can temporarily impair your ability to get an erection. To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking Vesuv.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>Vesuv is not indicated for use by women.</p><p><strong>Driving and using machines</strong></p><p>Vesuv can cause dizziness and can affect vision. You should be aware of how you react to Vesuv before you drive or use machinery.</p><p>Vesuv contains lactose</p><p>If you have been told by your doctor that you have intolerance to lactose, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended starting dose is 50 mg.</p><p>You should not take Vesuv more than once a day.</p><p>You should take Vesuv about one hour before you plan to have sex. Swallow the tablet whole with a glass of water.</p><p>If you feel that the effect of Vesuv is too strong or too weak, talk to your doctor or pharmacist.</p><p>Vesuv will only help you to get an erection if you are sexually stimulated. The amount of time</p><p>Vesuv takes to work varies from person to person, but it normally takes between half an hour and one hour. You may find that Vesuv takes longer to work if you take it with a heavy meal.</p><p>If Vesuv does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor.</p><p><strong>If you take more Vesuv than you should:</strong></p><p>You may experience an increase in side effects and their severity. Doses above 100 mg do not increase the efficacy.</p><p>You should not take more tablets than your doctor tells you to.</p><p>Contact your doctor if you take more tablets than you should.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them. The side effects reported in association with the use of Vesuv are usually mild to moderate and of a short duration.</p><p>If you experience any of the following serious side effects stop taking Vesuv and seek medical help immediately:</p><p>&bull; An allergic reaction -this occurs uncommonly (may affect up to 1 in 100 people)</p><p>Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.</p><p>&bull; Chest pains- this occurs uncommonly</p><p>If this occurs during or after intercourse</p><p>-Get in a semi-sitting position and try to relax.</p><p>-Do not use nitrates to treat your chest pain.</p><p>&bull; Prolonged and sometimes painful erections &ndash; this occurs rarely (may affect up to 1 in 1,000 people). If you have an erection which lasts for more than 4 hours, you should contact a doctor immediately.</p><p>&bull; A sudden decrease or loss of vision- this occurs rarely</p><p>&bull; Serious skin reactions- this occurs rarely</p><p>Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.</p><p>&bull; Seizures or fits- this occurs rarely</p><p>Other side effects:</p><p>Very common (may affect more than 1 in 10 people): headache.</p><p>Common (may affect up to 1 in 10 people): nausea, facial flushing, hot flush (symptoms include a sudden feeling of heat in your upper body), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness.</p><p>Uncommon (may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes/red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), , presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired.</p><p>Rare (may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eye, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small particles or spots in your vision, seeing halos around lights, dilation of the pupil of the eye, discolouration of the white of the eye, penile bleeding, presence of blood in semen, dry nose, swelling of the inside of the nose, feeling irritable and sudden decrease or loss of hearing.</p><p>From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely. Of note most but not all, of the men who experienced these side effects had heart problems before taking this medicine. It is not possible to determine whether these events were directly related to Vesuv.</p><p><strong>Reporting of side effects </strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Protect from light &amp; moisture.</p><p>Do not use this medicine after the expiry date which is stated on the blister strip and carton.</p><p>The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines that are no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is sildenafil. Each film coated tablet contains 25 mg, 50 mg or 100 mg of sildenafil citrate.</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate, Opadry II blue 31 K80956, Opadry clear 02K19253 and Purified water.</p><p>Film coat- lactose, hypromellose, titanium dioxide, triacetin, indigo carmine aluminum Lake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vesuv 50mg are Blue colored, round shaped biconvex coated tablets with a deep break line and debossed with "S" & "I" on either side of the break-line on one side and "2" debossed on other side.

Vesuv tablets are supplied as ALU/ PVC/ PVDC Blister Pack with 4 tablets.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Oman Pharmaceutical Products Co., LLC,. </strong></p><p>Plot No. 101, Raysut Industrial Estate,</p><p>Salalah, Sultanate of Oman.</p><p>Email: reg@omanpharma.com and pv@omanpharma.com&nbsp; &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">اقراص فيسوف تحتوي على المادة الفعالة سيلدينافيل الذي ينتمي إلى مجموعة من الأدوية تسمى مثبطات فوسفوديستريس 5 (PDE 5). وهو يعمل عن طريق المساعدة على استرخاء الأوعية الدموية في القضيب لديك، مما يسمح للدم بالتدفق إلى القضيب لديك عند الحصول مثار جنسيا. اقراص فيسوف - يساعد فقط على الحصول على الانتصاب إذا كنت مثار جنسيا.</p><p dir="RTL">اقراص فيسوف هو علاج للرجال الكبار مع عدم القدرة على الانتصاب، التي تعرف أحيانا باسم العجز الجنسي. ذلك عندما لا يستطيع الرجل أن يحصل، أو المحافظة على الثبات، في انتصاب القضيب المناسب للنشاط الجنسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>اقراص</strong> <strong>فيسوف</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من سيلدينافيل أو أي من المكونات الأخرى في هذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأدوية تسمى النترات، لأن الجمع مع سيلدينافيل قد يؤدي إلى انخفاض خطير في ضغط الدم. أخبر طبيبك إذا كنت تأخذ أي من هذه الأدوية التي غالبا ما تكون تعطى لتخفيف الذبحة الصدرية (أو &quot;ألم الصدر&quot;). إذا كنت غير متأكد، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أيا من الأدوية المعروفة باسم المانحين لأكسيد النيتريك مثل الأميل النتريت (&quot;بوبرس&quot;)، كما ان الجمع بينهما قد يؤدي أيضا إلى انخفاض خطير في ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ ريوسيجوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي الانصمامي المزمن (أي ارتفاع ضغط الدم في الرئتين الثانوية إلى جلطات الدم). وقد ثبت أن مثبطات PDE5،مثل اقراص فيسوف تؤدي الى زيادة تأثيرالمخفض للضغط من هذا الدواء. إذا كنت تأخذ ريوسيجوات أو غيرمتأكد أخبرطبيبك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة حادة في القلب أو الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مؤخرا سكتة دماغية أو أزمة قلبية، أو إذا كان لديك انخفاض في ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك بعض أمراض العيون الوراثية النادرة (مثل التهاب الشبكية الصباغي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك في أي وقت مضى فقدان الرؤية بسبب الاعتلال العصبي البصري الأمامي الدماغية الغير شرياني (NAION).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول اقراص فيسوف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك فقر الدم المنجلي (شذوذ من خلايا الدم الحمراء)، وسرطان الدم (سرطان خلايا الدم&nbsp;)، الورم النخاعي المتعدد (سرطان نخاع العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تشوه في القضيب أو مرض البايرونيس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في قلبك. يجب على الطبيب التحقق بعناية ما إذا كان قلبك يمكن أن يتحمل عبئا إضافيا من ممارسة الجنس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حاليا قرحة في المعدة أو مشاكل النزيف (مثل الهيموفيليا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا واجهت انخفاض أو فقدان البصر المفاجئ، توقف عن تناول اقراص فيسوف واتصل بطبيك فورا.</p><p dir="RTL">يجب عدم استخدام اقراص فيسوف مع أي علاجات عن طريق الفم أو المحلية الأخرى لعدم القدرة على الانتصاب.</p><p dir="RTL">يجب عدم استخدام اقراص فيسوف مع علاجات لارتفاع ضغط الدم الشرياني الرئوي (PAH) التي تحتوي على سيلدينافيل أو أي مثبطات PDE5 الأخرى.</p><p dir="RTL">يجب أن لا تتناول اقراص فيسوف إذا لم يكن لديك مشاكل في الانتصاب.</p><p dir="RTL">يجب أن لا تأخذ اقراص فيسوف إذا كنت امرأة.</p><p dir="RTL"><em>اعتبارات خاصة لمرضى الكلى أو الكبد</em><em> </em></p><p dir="RTL">يجب إخبار الطبيب إذا كان لديك مشاكل في الكلى او الكبد. طبيبك قد يقرر أن تأخذ جرعة أقل.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا ينبغي أن يعطى اقراص فيسوف للأفراد الذين تقل أعمارهم عن 18 عاما.</p><p dir="RTL"><strong>الأدوية الأخرى و </strong><strong>اقراص </strong><strong>فيسوف</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية آخرى.</p><p dir="RTL">قد تتداخل اقراص فيسوف مع بعض الأدوية، وخاصة تلك التي تستخدم لعلاج ألم في الصدر. في حالة وجود حالة طبية طارئة، يجب أن تخبر الطبيب أو الصيدلي أو الممرضة أن كنت قد تناولت اقراص فيسوف ومتى تناولتها. لا تتناول اقراص فيسوف مع الأدوية الأخرى ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن لا تتناول اقراص فيسوف إذا كنت تتناول أدوية تسمى النترات، كما ان الجمع بين هذه قد تؤدي الأدوية إلى انخفاض خطير في ضغط الدم. أخبر دائما طبيبك أو الصيدلي أو الممرضة إذا كنت تأخذ أي من هذه الأدوية التي غالبا ما تستخدم للتخفيف من الذبحة الصدرية (أو &quot;ألم الصدر&quot;).</p><p dir="RTL">يجب أن لا تتناول اقراص فيسوف إذا كنت تستخدم أيا من الأدوية المعروفة باسم المانحين النيتريك أكسيد مثل الأميل النتريت (&quot;بوبرس&quot;) كما ان الجمع في تناولهما قد يؤدي أيضا إلى انخفاض خطير في ضغط الدم.</p><p dir="RTL">اخبر طبيبك أو الصيدلي اذا كنت تتناول ريوسيجوات بالفعل</p><p dir="RTL">إذا كنت تأخذ أدوية المعروفة باسم مثبطات الأنزيم البروتيني، المستخدمه لعلاج فيروس نقص المناعة البشرية، طبيبك قد يبدأ لك بجرعة أقل (25 ملجم) من اقراص فيسوف.</p><p dir="RTL">بعض المرضى الذين يتناولون العلاج حاصرات ألفا لعلاج ارتفاع ضغط الدم أو تضخم في البروستاتا قد تواجه الدوخة أو الدوار الخفيف، والتي قد تكون ناجمة عن انخفاض ضغط الدم على الجلوس أو الوقوف بسرعة. شهد بعض المرضى هذه الأعراض عند تناول اقراص فيسوف مع حاصرات ألفا. هذا على أكثر احتمال يمكن أن يحدث في غضون 4 ساعات بعد تناول اقراص فيسوف. لتقليل فرصة حدوث هذه الأعراض ، يجب أن تكون على جرعة يومية اعتيادية من حاصرات ألفا قبل البدء اقراص فيسوف. طبيبك قد يبدأ لكم بجرعة أقل (25 ملجم) من اقراص فيسوف.</p><p dir="RTL"><strong>اقراص</strong> <strong>فيسوف</strong><strong> مع الطعام والشراب والكحول</strong></p><p dir="RTL">يمكن تناول اقراص فيسوف مع أو بدون الطعام. ومع ذلك، قد تجد أن اقراص فيسوف يستغرق وقتا أطول للبدء في العمل إذا كنت تناولته مع وجبة ثقيلة.</p><p dir="RTL">شرب الكحول يمكن أن يضعف مؤقتا قدرتك في الحصول على الانتصاب. للحصول على الفائدة القصوى من الدواء، وينصح بعدم شرب كميات كبيرة من الكحول قبل تناول اقراص فيسوف.</p><p dir="RTL"><strong>الحمل، والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">اقراص فيسوف لا يشار لاستخدامه من قبل النساء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">اقراص فيسوف يمكن أن يسبب الدوخة ويمكن أن يؤثر على الرؤية. يجب أن تكون على علم كيف تتفاعل مع اقراص فيسوف قبل&nbsp; القيام بالقيادة أو استخدام الآلات.</p><p dir="RTL"><strong>ت</strong><strong>حتوي </strong><strong>اقراص </strong><strong>فيسوف</strong><strong> على اللاكتوز:</strong></p><p dir="RTL">إذا أخبرك طبيبك أن لديك عدم تحمل<strong> اللاكتوز</strong>، اتصل بطبيبك قبل تناول هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">دائما تناول هذا الدواء تماما كما أبلغك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. الجرعة المبدئية الموصى بها هي 50 ملجم.</p><p dir="RTL"><strong><em>يجب أن لا تتناول </em></strong><strong><em>اقراص </em></strong><strong><em>فيسوف</em></strong><strong><em> أكثر من مرة في اليوم.</em></strong></p><p dir="RTL">يجب أن تتناول اقراص فيسوف حوالي ساعة واحدة قبل التخطيط لممارسة الجنس. ابتلع القرص بأكمله مع كوب من الماء.</p><p dir="RTL">إذا كنت تشعر بأن تأثير اقراص فيسوف قوي جدا أو ضعيف للغاية، تحدث مع طبيبك أو الصيدلي.</p><p dir="RTL">اقراص فيسوف تساعد فقط على الحصول على الانتصاب إذا كنت محفز جنسيا. مقدار الوقت اللذي تأخذه اقراص فيسوف لبدأ العمل يختلف من شخص لآخر، ولكن يستغرق عادة بين نصف ساعة وساعة واحدة. قد تجد أن اقراص فيسوف تستغرق وقتا أطول في العمل إذا ما تم تناوله مع وجبة ثقيلة.</p><p dir="RTL">إذا كانت اقراص فيسوف لا تساعدك في الحصول على الانتصاب، أو إذا كان الانتصاب لا يستمر طويلا بما يكفي لإتمام الجماع يجب عليك إخبار الطبيب بذلك.</p><p dir="RTL"><strong>إذا كنت تتناول أكثر مما يجب من </strong><strong>اقراص </strong><strong>فيسوف</strong><strong>:</strong></p><p dir="RTL">قد تواجه زيادة في الآثار الجانبية وشدتها. جرعات أعلى من 100 ملجم لا تزيد الفعالية.</p><p dir="RTL"><strong><em>يجب أن لا تتناول أقراص أكثر</em></strong><strong><em> </em></strong><strong><em>من</em></strong><strong><em> ما تم وصفه لك من قبل الطبيب.</em></strong></p><p dir="RTL">اتصل بطبيبك إذا كنت تتناول أقراص أكثر مما يجب.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثار جانبية على الرغم من أن الجميع لا تظهر لهم. الآثار الجانبية التي تم ذكرها مع استخدام اقراص فيسوف وعادة ما تكون خفيفة الى معتدلة وذات مدة قصيرة.</p><p dir="RTL">إذا كنت تواجه أي من الآثار الجانبية الجدية التالية توقف عن تناول اقراص فيسوف وقم بطلب المساعدة الطبية على الفور:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا رد الفعل التحسسي <strong>الغير شائع</strong> (قد تؤثر على ما يصل إلى 1 في كل 100 شخص)وتشمل أعراضه الأزيز المفاجئ، وصعوبة في التنفس أو دوار، وتورم في الجفون والوجه والشفاه أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآم الصدر &ndash; <strong>غير شائعة</strong></p><p dir="RTL">إذا كان هذا حدث أثناء أو بعد الجماع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ وضعية شبه الجلوس ومحاولة الاسترخاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تستخدام النترات</strong> لعلاج آلام الصدر الخاصة بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتصاب لفترات طويلة ومؤلمة في بعض الأحيان - يحدث هذا <strong>نادرا</strong> ما (قد يؤثر على ما يصل إلى 1 في كل 1000 شخص). إذا كان لديك انتصاب يستمر لأكثر من 4 ساعات، يجب عليك الاتصال بالطبيب على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مفاجئ أو فقدان البصر- يحدث هذا <strong>نادرا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية خطيرة - هذا يحدث <strong>نادرا</strong></p><p dir="RTL">الأعراض يمكن أن تشمل تقشير شديد وتورم في الجلد، وظهور تقرحات في الفم والأعضاء التناسلية وحول العينين والحمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات أو الصرع- يحدث هذا <strong>نادرا</strong></p><p dir="RTL"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL"><strong>الشائعة جدا</strong> (قد تؤثر على أكثر من 1 في كل 10 اشخاص): الصداع.</p><p dir="RTL"><strong>الشائعة </strong>(قد يؤثر على ما يصل إلى 1 في 10 اشخاص): الغثيان، احمرار الوجه، الهبات الساخنة (تشمل الأعراض شعور مفاجئ من الحرارة في الجزء العلوي من جسمك)، وعسر الهضم، الرؤية بلون خفيف ، وعدم وضوح الرؤية، واضطراب بصري، انسداد الأنف والدوخة .</p><p dir="RTL"><strong>الغير</strong> <strong>شائعة</strong> (قد يؤثر على ما يصل إلى 1 في كل 100 شخص): القيء والطفح الجلدي، وتهيج العين، احتقان العيون بالدم / احمرار العينين، وألم في العين، ورؤية ومضات من الضوء والسطوع المرئي، الحساسية للضوء، والعيون الدامعة، عنف بضربات القلب، سرعة ضربات القلب، وارتفاع ضغط الدم، وانخفاض ضغط الدم، وآلام في العضلات، والشعور بالنعاس، وانخفاض حاسة اللمس، والدوار، وطنين في الأذنين، وجفاف الفم، احتقان أو انغلاق الجيوب الأنفية ، والتهاب الغشاء المبطن للأنف (تشمل أعراض سيلان الأنف والعطس وانسداد الأنف )، وألم في الجزء العلوي من البطن ، مرض الارتجاع المعدي المريئي (تشمل الأعراض الحرقة)، ووجود دم في البول، وألم في الذراعين أو الساقين، والرعاف، والشعور بالسخونة والشعور بالتعب.</p><p dir="RTL"><strong>النادرة</strong> (قد يؤثر على ما يصل إلى 1 في كل 1000 شخص): إغماء والسكتة الدماغية والنوبات القلبية، عدم انتظام ضربات القلب، وانخفاض مؤقت في تدفق الدم إلى أجزاء من الدماغ، والشعور من احتقان الحلق والفم وخدر، ونزيف في الجزء الخلفي من العين، الرؤية المزدوجة، وانخفاض حدة الرؤية، والإحساس الغير طبيعي في العين، وتورم في العين أو الجفن، جزيئات صغيرة أو بقع في الرؤية، ورؤية هالات حول الأضواء، واتساع بؤبؤ العين، وتغير لون بياض العين، نزيف القضيب، وجود دم في السائل المنوي، والأنف الجاف، وتورم في داخل الأنف، الانفعال المفاجئ &nbsp;والشعور بانخفاض أو فقدان السمع.</p><p dir="RTL">من خبرة مرحلة ما بعد التسويق حالات الذبحة الصدرية الغير المستقرة (في القلب) والموت المفاجئ تم الإبلاغ عنها نادرا. وتجدر الإشارة أكثر ولكن ليس كل الجميع، من الرجال الذين عانوا من هذه الآثار الجانبية لديه مشاكل القلب قبل تناول هذا الدواء. وليس من الممكن تحديد ما إذا كانت هذه الأحداث كانت مرتبطة مباشرة إلى اقراص فيسوف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يحفظ بعيدا عن الضوء والرطوبة</p><p dir="RTL">يحفظ بعيدا عن متناول الأطفال</p><p dir="RTL">لا تستخدم الأقراص بعد تاريخ انتهاء الصلاحية المذكور على الشريط الاقراص والعبوة الكرتونية.</p><p dir="RTL">تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيلدينافيل. كل قرص يحتوي على 25 ملجم، 50 ملجم أو 100 ملجم من سيلدينافيل (كملح سيترات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الآخرى هي: ميكروكريستالين السليلوز ، فوسفات الهيدروجين الكالسيوم (لا مائي) والصوديوم كروسكاميلوز، ستيرات المغنيسيوم، اوبدري II الأزرق 31 K80956، واوبدري الواضح 02K19253.</p><p dir="RTL">طلاء الفيلم: اللاكتوز، هيدروكسي بروبيل ميثيل سيللوز ، ثاني أكسيد التيتانيوم، الترياسيتين ، بحيرة الألومنيوم النيلي القرمزي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">أقراص سيترات السيلدينافيل من 25 ملجم هي زرقاء اللون، دائرية، مغلفة بفيلم أقراص محدبة الوجهين يوجد على احد الجوانب &quot;124&quot; على جانب واحد و &quot;J&quot; على الجانب الآخر.</p><p dir="RTL">أقراص سيترات السيلدينافيل من 50 ملجم هي زرقاء اللون، دائرية، مغلفة بفيلم أقراص محدبة الوجهين يوجد على احد الجوانب مع &quot;125&quot; على جانب واحد و &quot;J&quot; على الجانب الآخر مع خط النتيجة.</p><p dir="RTL">أقراص سيترات السيلدينافيل من 25 ملجم هي زرقاء اللون، دائرية، مغلفة بفيلم أقراص محدبة الوجهين &nbsp;يوجد على احد الجوانب مع &quot;126&quot; على جانب واحد و &quot;J&quot; على الجانب الآخر مع خط النتيجة.</p><p dir="RTL">يتم توفير أقراص فيسوف على شكل حزمة نفطة ALU/PVC/PVDC مع 4 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة العمانية لمستحضرات الصيدلة ش.م.م</p><p dir="RTL">&nbsp;صلالة، سلطنة عمان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            شهر نوفمبر 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VESUV 50 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains Sildenafil citrate equivalent to 50 mg of Sildenafil. Excipient with known effect: 
VESUV 50 MG film-coated tablets Opadry II, blue-31K80956 contain Lactose (as monohydrate) – 40.000 % w/w
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
VESUV 50 mg film-coated tablets are Blue colored, round shaped biconvex coated tablets with a deep break line and debossed with "S" & "I" on either side of the break-line on one side and "2" debossed on other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VESUV is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.</p><p>In order for VESUVto be effective, sexual stimulation is required <strong>4.2 </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Use in adults</em></p><p>The recommended dose is 50 mg taken as needed approximately one hour before sexual activity. Based on efficacy and tolerability, the dose may be increased to 100 mg or decreased to 25 mg. The maximum recommended dose is 100 mg. The maximum recommended dosing frequency is once per day. If VESUVis taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2).</p><p><u>Special populations <em>Elderly</em></u></p><p>Dosage adjustments are not required in elderly patients (&ge; 65 years old).</p><p><em><u>Renal impairment</u></em></p><p>The dosing recommendations described in &ldquo;Use in adults&rdquo; apply to patients with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min).</p><p>Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) a 25 mg dose should be considered. Based on efficacy and tolerability, the dose may be increased step-wise to 50 mg up to 100 mg as necessary.</p><p><em><u>Hepatic impairment</u></em></p><p>Since sildenafil clearance is reduced in patients with hepatic impairment (e.g. cirrhosis) a 25 mg dose should be considered. Based on efficacy and tolerability, the dose may be increased step&shy;wise to 50 mg up to 100 mg as necessary.</p><p><em><u>Paediatric population</u></em></p><p>VESUVis not indicated for individuals below 18 years of age. <em><u>Use in patients taking other medicinal products</u></em></p><p>With the exception of ritonavir for which co-administration with Sildenafil is not advised (see Section 4.4) a starting dose of 25 mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5).</p><p>In order to minimise the potential of developing postural hypotension in patients receiving alpha-blocker treatment patients should be stabilized on alpha-blocker therapy prior to initiating Sildenafil treatment. In addition, initiation of Sildenafil at a dose of 25 mg should be considered (see sections 4.4 and 4.5).</p><p>Method of administration</p><p>For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see section 5.1), Sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
The co-administration of PDE5 inhibitors, including Sildenafil, with guanylatecyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
Agents for the treatment of erectile dysfunction, including Sildenafil, should not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure).

VESUVis contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
The safety of Sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa(a minority of these patients have genetic disorders of retinal phosphodiesterases).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.</p><p><u>Cardiovascular risk factors</u></p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1). Prior to prescribing sildenafil, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.</p><p>VESUVpotentiates the hypotensive effect of nitrates (see section 4.3).</p><p>Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of VESUV. Most, but not all, of these patients had pre-existing cardiovascular risk factors. Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of VESUVwithout sexual activity. It is not possible to determine whether these events are related directly to these factors or to other factors.</p><p><u>Priapism</u></p><p>Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie&#39;s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p>Prolonged erections and priapism have been reported with sildenafil in post-marketingexperience. In the event of an erection that persists for longer than 4 hours, the patient shouldseekimmediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.</p><p><u>Concomitant use with other PDE5 inhibitors or other treatments for erectile dysfunction</u></p><p>The safety and efficacy of combinations of sildenafil with other PDE5 inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil (REVATIO), or other treatments for erectile dysfunction have not been studied. Therefore the use of such combinations is not recommended.</p><p><u>Effects on vision</u></p><p>Cases of visual defects have been reported spontaneously in connection with the intake of sildenafil and other PDE5 inhibitors (see section 4.8). Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition, have been reported spontaneously and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors (see section 4.8). Patients should be advised that in the event of any sudden visual defect, they should stop taking VESUVand consult a physician immediately (see section 4.3).</p><p><u>Concomitant use with ritonavir</u></p><p>Co-administration of sildenafil with ritonavir is not advised (see section 4.5). <u>Concomitant use with alpha-blockers</u></p><p>Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5). This is most likely to occur within 4 hours post sildenafil dosing. In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to initiating Sildenafil treatment. Initiation of sildenafil at a dose of 25 mg should be considered (see section 4.2). In addition, physicians should advise patients what to do in the event of postural hypotensive symptoms.</p><p><u>Effect on bleeding</u></p><p>Studies with human platelets indicate that sildenafil potentiates the anti aggregatory effect of sodium nitroprusside <em>in vitro</em>. There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration. Therefore sildenafil should be administered to these patients only after careful benefit-risk assessment.</p><p>The film coating of the tablet contains lactose. VESUV should not be administered to men with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.</p><p><u>Women</u></p><p>VESUV is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on sildenafil</u></p><p><em>In vitro studies</em></p><p>Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.</p><p><em>In vivo studies</em></p><p>Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, cimetidine). Although no increased incidence of adverse events was observed in these patients, when sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25 mg should be considered.</p><p>Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil <sub>Cmax</sub> and a 1,000% (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone. This is consistent with ritonavir&#39;s marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics. Based on these pharmacokinetic results co-administration of sildenafil with ritonavir is not advised (see section 4.4) and in any event the maximum dose of sildenafil should under no circumstances exceed 25 mg within 48 hours.</p><p>Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil <sub>Cmax</sub> and a 210% increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics (see section 4.2). Stronger CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected to have greater effects.</p><p>When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite.</p><p>Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.</p><p>Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest increases in plasma levels of sildenafil.</p><p>Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.</p><p>Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and <sub>Cmax, </sub>respectively. Therefore, concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma concentrations of sildenafil.</p><p>Nicorandil is a hybrid of potassium channel activator and nitrate. Due to the nitrate component it has the potential to result in a serious interaction with sildenafil.</p><p><u>Effects of sildenafil on other medicinal products </u></p><p><em>In vitro studies</em></p><p>Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 <sub>(IC50 </sub>&gt;150 &mu;M). Given sildenafil peak plasma concentrations of approximately 1 &mu;M after recommended doses, it is unlikely that VESUVwill alter the clearance of substrates of these isoenzymes.</p><p>There are no data on the interaction of sildenafil and non-specificphosphodiesterase inhibitors such as theophylline or dipyridamole.</p><p>&nbsp;</p><p><em>In vivo studies</em></p><p>Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see section 4.3).</p><p>Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).</p><p>Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4). In three specific drug-drugs interactionstudies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed. When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and light-headedness, but not syncope.</p><p>No significant interactions were shown when sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.</p><p>Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg).</p><p>Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl.</p><p>Pooling of the following classes of antihypertensive medication; diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally-acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment. In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg. The corresponding additional reduction in supine diastolic blood pressure was 7 mmHg. These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section 5.1).</p><p>Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.</p><p>In healthy male volunteers, sildenafil at steady state (80 mg t.i.d.) resulted in a 49.8% increase in bosentan AUC and a 42% increase in bosentan<sub>Cmax</sub> (125 mg b.i.d.).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VESUVis not indicated for use by women.</p><p>There are no adequate and well-controlled studies in pregnant or breast-feeding women.</p><p>No relevant adverse effects were found in reproduction studies in rats and rabbits following oral administration of sildenafil.</p><p>There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to VESUV, before driving or operating machinery</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of VESUVis based on 9,570 patients in 74 double blind placebo-controlled clinical studies. The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and blurred vision.</p><p>Adverse reactions from post-marketing surveillance has been gathered covering an estimated period &gt;10 years. Because not all adverse reactions are reported to the Marketing Authorisation Holder and included in the safety database, the frequencies of these reactions cannot be reliably determined.</p><p><u>Tabulated list of adverse reactions</u></p><p>In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (?1/10), common (?1/100 to &lt;1/10), uncommon (?1/1,000 to &lt;1/100), rare (?1/10,000 to, 1/1,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through post-marketing surveillance</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:698px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 and</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1,000 and</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge; 1/10,000 and</strong></p><p><strong>&lt;1/1,000)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence, Hypoaesthesia</p></td><td style="vertical-align:top"><p>Cerebrovascular accident, Transient ischaemic attack, Seizure*, Seizure</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>recurrence*, Syncope</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual colour distortions**, Visual disturbance, Vision blurred</p></td><td style="vertical-align:top"><p>Lacrimation disorders***, Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual brightness, Conjunctivitis</p></td><td style="vertical-align:top"><p>Non-arteritic anterior ischaemic optic neuropathy (NAION)*,* Retinal vascular occlusion*, Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect, Diplopia, Visual acuity reduced, Myopia, Asthenopia, Vitreous floaters, Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye disorder, Conjunctivalhyperaemia, Eye irritation, Abnormal sensation in eye, Eyelid oedema, Scleral discoloration</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo, Tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Sudden cardiac death*, Myocardial infarction, Ventricular arrhythmia*, Atrial fibrillation, Unstable angina</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing, Hot flush</p></td><td style="vertical-align:top"><p>Hypertension, Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Epistaxis, Sinus congestion</p></td><td style="vertical-align:top"><p>Throat tightness, Nasal oedema, Nasal dryness</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea, Dyspepsia</p></td><td style="vertical-align:top"><p>Gastro oesophageal reflux disease, Vomiting, Abdominal pain upper, Dry mouth</p></td><td style="vertical-align:top"><p>Hypoaesthesia oral</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>Skin and</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>Rash</p></td><td><p>Stevens-Johnson</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syndrome (SJS)*,* Toxic Epidermal Necrolysis (TEN) *</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia, Pain in extremity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Penile haemorrhage, Priapism*, Haematospermia, Erection increased</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest pain, Fatigue, Feeling hot</p></td><td style="vertical-align:top"><p>Irritability</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>Heart rate increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>*</strong>Reported during post-marketing surveillance only</p><p>**Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia ***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased.</p><p>In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals; Drugs used in erectile dysfunction.</p><p>ATC Code: G04BE03. <strong><u>Mechanism of action </u></strong></p><p>Sildenafil is an oral therapy for erectile dysfunction. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis.</p><p>&nbsp;</p><p>The physiological mechanism responsible for erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide then activates the enzyme guanylatecyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.</p><p>Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP. Sildenafil has a peripheral site of action on erections. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Studies <em>in vitro </em>have shown that sildenafil is selective for PDE5, which is involved in the erection process. Its effect is more potent on PDE5 than on other known phosphodiesterases. There is a 10-fold selectivity over PDE6 which is involved in the phototransduction pathway in the retina. At maximum recommended doses, there is an 80-fold selectivity over PDE1, and over 700-fold over PDE 2, 3, 4, 7, 8, 9, 10 and 11. In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>Two clinical studies were specifically designed to assess the time window after dosing during which sildenafil could produce an erection in response to sexual stimulation. In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12&shy;37 minutes) on sildenafil. In a separate RigiScan study, sildenafil was still able to produce an erection in response to sexual stimulation 4-5 hours post-dose.</p><p>Sildenafil causes mild and transient decreases in blood pressure which, in the majority of cases, do not translate into clinical effects. The mean maximum decreases in supine systolic blood pressure following 100 mg oral dosing of sildenafil was 8.4 mmHg. The corresponding change in supine diastolic blood pressure was 5.5 mmHg. These decreases in blood pressure are consistent with the vasodilatory effects of sildenafil, probably due to increased cGMP levels in vascular smooth muscle. Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG.</p><p>In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patientswith severe coronary artery disease (CAD) (&gt;70% stenosis of at least one coronary artery), themean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline. Mean pulmonary systolic blood pressure decreased by 9%. Sildenafil showed no effect on cardiac output, and did not impair blood flow through the stenosed coronary arteries.</p><p>A double-blind, placebo-controlled exercise stress trial evaluated 144 patients with erectile dysfunction and chronic stable angina who regularly received anti-anginal medicinal products (except nitrates). The results demonstrated no clinically relevant differences between sildenafil and placebo in time to limiting angina.</p><p>Mild and transient differences in colour discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose. The postulated mechanism for this change in colour discrimination is related to inhibition of PDE6, which is involved in the photo transduction cascade of the retina. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n=9), sildenafil (single dose, 100 mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).</p><p>There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers (see section 4.6).</p><p><strong>Further information on clinical trials</strong></p><p>In clinical trials sildenafil was administered to more than 8000 patients aged 19-87. The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%). The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3).</p><p>In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo. In controlled clinical trials, the discontinuation rate due to sildenafil was low and similar to placebo.</p><p>Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%). The safety and efficacy of sildenafil was maintained in long term studies.</p><p><u>Paediatric population</u></p><p><u>The European Medicines Agency has waived the obligation to submit the results of studies with VESUVin all subsets of the paediatric population for the treatment of erectile dysfunction. See section 4.2 for information on paediatric use. </u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. The mean absolute oral bioavailability is 41% (range 25-63%). After oral dosing of sildenafil AUC and <sub>Cmax</sub> increase in proportion with dose over the recommended dose range (25-100 mg).</p><p>When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in <sub>tmax</sub> of 60 minutes and a mean reduction in <sub>Cmax</sub> of 29%.</p><p><strong><u>Distribution</u></strong></p><p>The mean steady state volume of distribution (Vd) for sildenafil is 105 l, indicating distribution into the tissues. After a single oral dose of 100 mg, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL (CV 40%). Since sildenafil (and its major circulating N-desmethylmetabolite) is 96% bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM). Protein binding is independent of total drug concentrations.</p><p>In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing.</p><p><strong><u>Biotransformation </u></strong></p><p>Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-demethylation of sildenafil. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an <em>in vitro </em>potency for PDE5 approximately 50% that of the parent drug. Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil. The N-desmethyl metabolite is further metabolised, with a terminal half life of approximately 4 h.</p><p><strong><u>Elimination </u></strong></p><p>The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half life of 3-5 h. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of administered oral dose).</p><p><strong><u>Pharmacokinetics in special patient groups </u></strong></p><p><strong>Elderly</strong></p><p>Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethylmetabolite compared to those seen in healthy younger volunteers (18-45 years). Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately 40%.</p><p><strong>Renal insufficiency</strong></p><p>In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single oral dose. The mean AUC and <sub>Cmax</sub> of the N-desmethyl metabolite increased up to 126% and up to 73% respectively, compared to age-matched volunteers with no renal impairment. However, due to high inter-subject variability, these differences were not statistically significant. In volunteers with severe renal impairment (creatinine clearance &lt; 30 mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and <sub>Cmax</sub> of 100% and 88% respectively compared to age-matched volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC and C<sub>max</sub>values were significantly increased by 200% and 79% respectively.</p><p><strong>Hepatic insufficiency</strong></p><p>In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and <sub>Cmax</sub> (47%) compared to age-matched volunteers with no hepatic impairment. The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>Microcrystalline cellulose (Avicel PH-112), Calcium hydrogen phosphate anhydrous (Emcompress), Croscarmellose sodium, Magnesium stearate (MF-2-V), Opadry II blue 31 K80956 (VESUV50 &amp; 100), Opadry clear 02K19253 &amp; Purified water,</p><p>Film coat:</p><p>Opadry II blue 31K80956</p><p><em>(Lactose Monohydrate, HPMC 2910/Hypromellose 15 cP, Titanium Dioxide, Triacetin, FD&amp;C BLUE #2/Indigo Carmine Aluminum Lake).</em></p><p>Opadry clear 02K19253 (<em>HPMC 2910/Hypromellose 5 cP, Triacetin).</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>Protect from light &amp; moisture</p><p>Keep out of reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ALU/ PVC/ PVDC Blister Pack 4 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oman Pharmaceutical Products Co. L.L.C.
Plot No 101, Raysut Industrial Estate, 
Salalah, Sultanate of Oman

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>